TabsDetailsBasic DetailsDate Posted: Monday, June 24, 2019Status: CompleteMedical Product: doxylamine, granisetron, metoclopramide HCL, netupitant/palonosetron HCl, ondansetron, palonosetron, prochlorperazine, promethazine HCl, succinate/pyridoxine HClHealth Outcome(s): exposure in pregnancyDescription: This report contains the prevalence of antiemetic use among women of reproductive age who delivered a liveborn infant in the Mini-Sentinel Distributed Database (MSDD). Results for antiemetic use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.Data from January 1, 2001 to December 31, 2014 from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on November 10, 2015. Read More Deliverables (1)Mini-Sentinel Modular Program Report: Antiemetic Use During PregnancyAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2001 to December 31, 2014Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Females 0 to 54 years of ageData Sources: Mini-Sentinel Distributed Database (MSDD)Related Links: Antiemetic Use Among Pregnant Women in the United States: The Escalating Use of Ondansetron2016 ICPE Presentation: Ondasetron Use Among Pregnancies Identified in the Sentinel Distributed Database
